Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
Trial details
- Registry ID
- NCT05320393
- Drugs studied
- OnabotulinumtoxinA, PrabotulinumtoxinA-Xvfs
TrialRedline tracks 1 clinical trial sponsored by Evolus, Inc.: 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar LinesNCT05320393 | OnabotulinumtoxinA, PrabotulinumtoxinA-Xvfs | Completed | 2023-05-22Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2019-02-01Day | PrabotulinumtoxinA-XvfsEvolus, Inc. · EOLS | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761085", "applicant_as_listed_by_fda": "EVOLUS INC", "brand_names": ["JEUVEAU"], "active_ingredients": ["PRABOTULINUMTOXINA-XVFS"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20190201", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |
Names as written in the registry records.